BTIG Research Reiterates “Buy” Rating for Cullinan Therapeutics (NASDAQ:CGEM)

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reaffirmed by investment analysts at BTIG Research in a research note issued to investors on Friday, Benzinga reports. They currently have a $40.00 price objective on the stock. BTIG Research’s price target points to a potential upside of 172.05% from the stock’s current price.

Several other equities analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wedbush increased their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. TD Cowen raised shares of Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright boosted their price objective on shares of Cullinan Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cullinan Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $33.71.

Cullinan Therapeutics Price Performance

Shares of NASDAQ:CGEM traded down $0.74 on Friday, hitting $14.70. 863,157 shares of the company’s stock were exchanged, compared to its average volume of 895,846. The business’s 50 day simple moving average is $19.83 and its two-hundred day simple moving average is $16.71. The stock has a market capitalization of $946.29 million, a price-to-earnings ratio of -4.74 and a beta of 0.02. Cullinan Therapeutics has a 12 month low of $5.68 and a 12 month high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.01). Equities analysts forecast that Cullinan Therapeutics will post -3.08 EPS for the current fiscal year.

Insider Activity at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total value of $172,560.00. Following the completion of the transaction, the insider directly owned 158,844 shares of the company’s stock, valued at approximately $3,426,265.08. The trade was a 4.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 46,000 shares of company stock valued at $922,920 in the last quarter. 8.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CGEM. BlackRock Inc. purchased a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at approximately $95,289,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Cullinan Therapeutics in the second quarter valued at approximately $28,039,000. Boothbay Fund Management LLC acquired a new stake in shares of Cullinan Therapeutics in the fourth quarter valued at approximately $12,803,000. Boone Capital Management LLC acquired a new stake in shares of Cullinan Therapeutics in the second quarter valued at approximately $12,828,000. Finally, Elmind Capital LP purchased a new position in Cullinan Therapeutics during the second quarter worth approximately $12,564,900. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG reaffirmed its Buy rating and $40 price target, implying substantial upside from recent trading levels. The endorsement suggests the firm continues to see significant value in Cullinan’s pipeline despite recent volatility. Benzinga analyst rating report
• Positive Sentiment: Cullinan outlined several fourth-quarter 2026 catalysts across its T-cell engager portfolio. Velinotamig data in systemic lupus erythematosus is expected at the ACR Convergence meeting in November, while CLN-978 data in lupus, rheumatoid arthritis and Sjögren’s disease, plus updated CLN-049 Phase 1 data, are planned for December. Cullinan fourth-quarter 2026 milestones
• Neutral Sentiment: The company’s fourth-quarter updates span three T-cell engager programs, giving investors multiple upcoming opportunities to assess efficacy and safety, although the eventual impact will depend on the clinical results. Cullinan T-cell engager pipeline milestones
• Neutral Sentiment: Reported short-interest data showed no shares sold short as of September 24, indicating that short selling was not a significant recorded source of pressure; the unusual zero figure may limit its usefulness as a sentiment indicator.
• Negative Sentiment: Cullinan delayed an early-stage clinical data update for its arthritis therapy until December. The postponement removed a near-term catalyst and contributed to investor disappointment. Cullinan delays arthritis drug data
• Negative Sentiment: Investor concerns also remain focused on zipalertinib’s safety profile. Those concerns have overshadowed otherwise strong Phase 3 lung-cancer data and increased uncertainty around the program’s commercial potential. CGEM zipalertinib analysis

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.